
Christoph Westphal
SlowingNamed in filings at Longwood
- Board seats filed
- 9
all filings on record

Named in filings at Longwood
all filings on record
last 24 months
from a verified or cited source
| Newleos Therapeutics | Biotech & pharma | February 2025 | None on file |
| Immunitas Therapeutics | Biotech & pharma | August 2021 | None on file |
| ImmuneID | Biotech & pharma | December 2020 | None on file |
| Werewolf Therapeutics | Biotech & pharma | August 2019 | MPM BioVentures |
| TScan Therapeutics | Biotech & pharma | July 2019 | Bessemer Venture Partners |
| Pyxis Oncology | Biotech & pharma | June 2019 | Agent Capital |
| Recros Medica | Medical devices | December 2018 | None on file |
| Flex Pharma | Biotech & pharma | July 2014 | Bessemer Venture Partners |
| Verastem | Biotech & pharma | February 2014 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The category is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Categories of companies where filings name Christoph Westphal on the board, based on 9 filed seats with a verified or cited source.